newsfilter
← Latest News
PR Newswire·

Medivir presents data on additive activity of fostrox in combination with Lenvima or sorafenib in non-clinical tumor models at ILCA

STOCKHOLM, Sept. 7, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancers with high unmet medical needs, today announces that data on